Clinical Alternatives for Reducing Harm Using E-cigarettes
Launched by MEDICAL UNIVERSITY OF SOUTH CAROLINA · Jun 18, 2025
Trial Information
Current as of July 22, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying whether switching completely from regular cigarettes to e-cigarettes can help people with cancer who smoke but do not want to use traditional quitting methods. Quitting smoking is very important for patients in cancer care, but many refuse treatments like counseling or medication. This study will look at using e-cigarettes as a safer alternative to reduce harm from smoking in these patients.
To take part, you must be at least 21 years old, currently smoking, and have declined all usual quitting treatments offered through a hospital program. You also need to speak English and not have used e-cigarettes or other quitting aids recently. Pregnant women and people in prison cannot join. If you participate, you will be asked to switch completely from cigarettes to e-cigarettes, and researchers will follow your progress to see if this helps reduce harm. The study is not yet recruiting but will include about 208 patients receiving cancer care.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • age 21+,
- • identified as smoking in their medical record and self-report of current smoking within the past 30 days
- • refused traditional treatment options through the opt-out HCC Tobacco Treatment Program
- • English speaking;
- Exclusion Criteria:
- • currently taking part in any TTP or using cessation medication (i.e., taking NRT or other cessation medications, enrolled in the Quitline, or in another study),
- • use of e-cigarettes in the past 30 days,
- • currently imprisoned,
- • pregnant women.
About Medical University Of South Carolina
The Medical University of South Carolina (MUSC) is a leading academic health center dedicated to advancing medical research and improving patient care through innovative clinical trials. With a strong emphasis on translational medicine, MUSC leverages its extensive resources and expertise to facilitate groundbreaking studies across various medical disciplines. The institution is committed to fostering collaboration among researchers, healthcare professionals, and patients, ensuring that cutting-edge discoveries translate into effective treatments. As a pioneer in health education and research, MUSC plays a vital role in shaping the future of medicine and enhancing health outcomes in the community and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Alana Rojewski
Principal Investigator
Medical University of South Carolina
Tracy Smith
Principal Investigator
Medical University of South Carolina
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported